ZBH Stock to Gain From Volume Growth Amid Rising Costs
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.
Zimmer Biomet Focuses on Innovation Amid Growing Competition
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but recent organic growth and M&A actions are promising, with mid-single digit sales growth projected. The $1.2 billion Paragon 28 acquisition enhances foot and ankle orthopedics, despite short-term EPS dilution, and boosts Zimmer Biomet's growth profile.
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments.
Why Is Zimmer Biomet Stock Trading Lower On Thursday?
On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - President and Chief Executive Officer Suketu Upadhyay - CFO and EVP, Finance, Operations and Supply Chain Conference Call Participants Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley Steven Lichtman - Oppenheimer and Company Matt Taylor - Jefferies David Roman - Goldman Sachs Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Danielle Antalffy - UBS Travis Steed - Bank of America Rick Wise - Stifel Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06, 2025.
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet forecasts 2025 profit below estimates
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.
Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago.
